Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	NGM Biopharmaceuticals	IGM Biosciences	Revance Therapeutics	Amarin	Madrigal Pharmaceuticals
Symbol	NASDAQ:NGM	NASDAQ:IGMS	NASDAQ:RVNC	NASDAQ:AMRN	NASDAQ:MDGL
Price Information
Current Price	$28.58	$68.76	$29.06	$4.38	$134.70
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.7	1.7	1.7	1.6	1.5
Analysis Score	3.6	3.4	3.5	3.2	2.4
Community Score	3.4	2.5	2.6	3.1	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	2.5	1.7	0.8	2.5
Earnings & Valuation Score	0.0	0.0	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$39.11	$98.88	$38.50	$10.50	$167.60
% Upside from Price Target	36.85% upside	43.80% upside	32.48% upside	139.73% upside	24.42% upside
Trade Information
Market Cap	$2.20 billion	$2.20 billion	$2.08 billion	$1.72 billion	$2.23 billion
Beta	1.97	-1.12	1.42	2.58	1.19
Average Volume	255,723	195,850	429,857	6,371,316	162,137
Sales & Book Value
Annual Revenue	$103.54 million	N/A	$410,000.00	$429.76 million	N/A
Price / Sales	21.26	N/A	5,069.84	4.01	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.96 per share	$7.88 per share	$5.00 per share	$1.63 per share	$27.00 per share
Price / Book	5.76	N/A	5.81	2.69	N/A
Profitability
Net Income	$-42,790,000.00	$-43,130,000.00	$-159,430,000.00	$-22,650,000.00	$-83,950,000.00
EPS	($0.85)	($4.80)	($3.67)	($0.07)	($5.45)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	36.50	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-91.64%	N/A	-5,818.87%	-2.69%	N/A
Return on Equity (ROE)	-29.47%	-33.30%	-85.72%	-2.70%	-47.64%
Return on Assets (ROA)	-25.58%	-30.28%	-44.85%	-1.72%	-43.21%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.48%	N/A	N/A
Current Ratio	8.01%	13.90%	7.07%	2.72%	6.84%
Quick Ratio	8.01%	13.90%	7.01%	2.27%	6.84%
Ownership Information
Institutional Ownership Percentage	49.56%	47.60%	74.35%	37.78%	74.24%
Insider Ownership Percentage	50.40%	79.34%	4.80%	2.75%	41.89%
Miscellaneous
Employees	210	107	470	1,000	42
Shares Outstanding	77.02 million	32.01 million	71.53 million	393.44 million	16.59 million
Next Earnings Date	8/11/2021 (Estimated)	8/5/2021 (Estimated)	8/5/2021 (Estimated)	8/3/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Chardan Capital Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc investing.com - May 10 at 4:04 PM
	Madrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly Earnings Results americanbankingnews.com - May 9 at 1:16 PM
	Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc investing.com - May 9 at 9:24 AM
	-$3.75 EPS Expected for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) This Quarter americanbankingnews.com - May 8 at 9:14 AM
	Madrigal: Q1 Earnings Snapshot sfgate.com - May 6 at 11:53 AM
	Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights finance.yahoo.com - May 6 at 11:53 AM
	Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High at $137.81 americanbankingnews.com - April 27 at 1:38 PM
	We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate nasdaq.com - April 27 at 8:41 AM
	Zacks: Analysts Expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to Announce -$3.78 Earnings Per Share americanbankingnews.com - April 21 at 12:14 AM
	Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $121.19 americanbankingnews.com - April 20 at 12:50 PM
	MDGL Makes Notable Cross Below Critical Moving Average nasdaq.com - March 23 at 5:42 PM
	Madrigal Pharmaceuticals, Inc.(MDGL) fool.com - March 11 at 9:27 AM
	Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL) smarteranalyst.com - March 2 at 12:35 PM
	Madrigal: 4Q Earnings Snapshot \| Raleigh News & Observer newsobserver.com - February 25 at 7:22 AM
	Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights finance.yahoo.com - February 25 at 7:22 AM
	Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights finance.yahoo.com - February 25 at 7:22 AM
	Market insanity hits MicroCap fxstreet.com - February 5 at 10:14 AM
	The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street msn.com - February 5 at 10:14 AM
	Is MDGL A Good Stock To Buy Now? finance.yahoo.com - December 17 at 12:30 AM
	Here's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation finance.yahoo.com - November 24 at 12:09 PM
	MDGL Nov 2020 110.000 call uk.finance.yahoo.com - November 21 at 8:03 PM
	MDGL Nov 2020 80.000 call uk.finance.yahoo.com - November 20 at 10:43 PM
	MDGL Nov 2020 155.000 call uk.finance.yahoo.com - November 20 at 5:41 PM
	Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow seekingalpha.com - November 19 at 8:15 PM
	Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ... apnews.com - November 14 at 1:45 PM

Date	Company	Brokerage	Action
3/11/2021	NGM Biopharmaceuticals	Raymond James	Boost Price Target
3/11/2021	NGM Biopharmaceuticals	Chardan Capital	Boost Price Target
2/9/2021	NGM Biopharmaceuticals	The Goldman Sachs Group	Boost Price Target
1/5/2021	NGM Biopharmaceuticals	Stifel Nicolaus	Reiterated Rating
12/21/2020	NGM Biopharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/21/2020	NGM Biopharmaceuticals	Smith Barney Citigroup	Boost Price Target
12/14/2020	NGM Biopharmaceuticals	B. Riley	Boost Price Target
7/30/2020	NGM Biopharmaceuticals	Piper Sandler	Initiated Coverage
6/4/2020	NGM Biopharmaceuticals	BMO Capital Markets	Initiated Coverage
3/23/2020	NGM Biopharmaceuticals	Cowen	Reiterated Rating
3/31/2021	IGM Biosciences	Truist	Boost Price Target
3/31/2021	IGM Biosciences	HC Wainwright	Reiterated Rating
1/29/2021	IGM Biosciences	Royal Bank of Canada	Initiated Coverage
12/22/2020	IGM Biosciences	Wedbush	Downgrade
7/16/2020	IGM Biosciences	Robert W. Baird	Initiated Coverage
5/28/2020	IGM Biosciences	SunTrust Banks	Initiated Coverage
3/12/2020	IGM Biosciences	Wolfe Research	Initiated Coverage
1/6/2020	IGM Biosciences	Piper Jaffray Companies	Boost Price Target
10/14/2019	IGM Biosciences	Jefferies Financial Group	Initiated Coverage
10/14/2019	IGM Biosciences	Guggenheim	Initiated Coverage
5/11/2021	Revance Therapeutics	Mizuho	Lower Price Target
4/14/2021	Revance Therapeutics	Needham & Company LLC	Reiterated Rating
10/26/2020	Revance Therapeutics	Barclays	Boost Price Target
3/27/2020	Revance Therapeutics	William Blair	Reiterated Rating
2/1/2021	Amarin	SVB Leerink	Boost Price Target
9/29/2020	Amarin	JPMorgan Chase & Co.	Initiated Coverage
9/8/2020	Amarin	Cantor Fitzgerald	Lower Price Target
6/3/2020	Amarin	Oppenheimer	Reiterated Rating
5/5/2020	Amarin	Northland Securities	Initiated Coverage
5/4/2020	Amarin	Aegis	Boost Price Target
11/23/2020	Madrigal Pharmaceuticals	Evercore ISI	Reiterated Rating
11/12/2020	Madrigal Pharmaceuticals	Canaccord Genuity	Lower Price Target

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources